Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (19)

2024

  1. 18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study

    Expert Review of Hematology, Vol. 17, Núm. 1-3, pp. 95-100

  2. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

2023

  1. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  2. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  3. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

  2. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

2021

  1. Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib

    British Journal of Haematology

  2. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study

    Cancer Medicine, Vol. 10, Núm. 21, pp. 7629-7640

2019

  1. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471

  2. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831

2014

  1. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

    Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307

2013

  1. Guía de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocítica crónica

    Medicina Clinica

2009

  1. Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 4, pp. 512-516

2008

  1. Update on pulmonary infections in patients with hematologic malignancies and hematopoietic stem cell recipients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. SUPPL. 3, pp. 58-71

2005

  1. Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics

    Swiss Medical Weekly

2004

  1. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

    Bone Marrow Transplantation, Vol. 34, Núm. 1, pp. 13-20

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743